Cargando…
Bone marrow activation in response to metabolic syndrome and early atherosclerosis
AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascu...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113301/ https://www.ncbi.nlm.nih.gov/pubmed/35567559 http://dx.doi.org/10.1093/eurheartj/ehac102 |
_version_ | 1784709559392141312 |
---|---|
author | Devesa, Ana Lobo-González, Manuel Martínez-Milla, Juan Oliva, Belén García-Lunar, Inés Mastrangelo, Annalaura España, Samuel Sanz, Javier Mendiguren, José M Bueno, Hector Fuster, Jose J Andrés, Vicente Fernández-Ortiz, Antonio Sancho, David Fernández-Friera, Leticia Sanchez-Gonzalez, Javier Rossello, Xavier Ibanez, Borja Fuster, Valentin |
author_facet | Devesa, Ana Lobo-González, Manuel Martínez-Milla, Juan Oliva, Belén García-Lunar, Inés Mastrangelo, Annalaura España, Samuel Sanz, Javier Mendiguren, José M Bueno, Hector Fuster, Jose J Andrés, Vicente Fernández-Ortiz, Antonio Sancho, David Fernández-Friera, Leticia Sanchez-Gonzalez, Javier Rossello, Xavier Ibanez, Borja Fuster, Valentin |
author_sort | Devesa, Ana |
collection | PubMed |
description | AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND RESULTS: Whole body vascular (18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ((18)F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8–53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM (18)F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3–L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by (18)F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis—characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts—and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity ((18)F-FDG uptake). The co-occurrence of BM activation and arterial (18)F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). CONCLUSION: In apparently healthy individuals, BM (18)F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development. [Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318]. |
format | Online Article Text |
id | pubmed-9113301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91133012022-05-18 Bone marrow activation in response to metabolic syndrome and early atherosclerosis Devesa, Ana Lobo-González, Manuel Martínez-Milla, Juan Oliva, Belén García-Lunar, Inés Mastrangelo, Annalaura España, Samuel Sanz, Javier Mendiguren, José M Bueno, Hector Fuster, Jose J Andrés, Vicente Fernández-Ortiz, Antonio Sancho, David Fernández-Friera, Leticia Sanchez-Gonzalez, Javier Rossello, Xavier Ibanez, Borja Fuster, Valentin Eur Heart J Clinical Research AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND RESULTS: Whole body vascular (18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ((18)F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8–53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM (18)F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3–L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by (18)F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis—characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts—and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity ((18)F-FDG uptake). The co-occurrence of BM activation and arterial (18)F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). CONCLUSION: In apparently healthy individuals, BM (18)F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development. [Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318]. Oxford University Press 2022-03-11 /pmc/articles/PMC9113301/ /pubmed/35567559 http://dx.doi.org/10.1093/eurheartj/ehac102 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Devesa, Ana Lobo-González, Manuel Martínez-Milla, Juan Oliva, Belén García-Lunar, Inés Mastrangelo, Annalaura España, Samuel Sanz, Javier Mendiguren, José M Bueno, Hector Fuster, Jose J Andrés, Vicente Fernández-Ortiz, Antonio Sancho, David Fernández-Friera, Leticia Sanchez-Gonzalez, Javier Rossello, Xavier Ibanez, Borja Fuster, Valentin Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title | Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title_full | Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title_fullStr | Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title_full_unstemmed | Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title_short | Bone marrow activation in response to metabolic syndrome and early atherosclerosis |
title_sort | bone marrow activation in response to metabolic syndrome and early atherosclerosis |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113301/ https://www.ncbi.nlm.nih.gov/pubmed/35567559 http://dx.doi.org/10.1093/eurheartj/ehac102 |
work_keys_str_mv | AT devesaana bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT lobogonzalezmanuel bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT martinezmillajuan bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT olivabelen bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT garcialunarines bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT mastrangeloannalaura bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT espanasamuel bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT sanzjavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT mendigurenjosem bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT buenohector bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT fusterjosej bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT andresvicente bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT fernandezortizantonio bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT sanchodavid bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT fernandezfrieraleticia bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT sanchezgonzalezjavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT rosselloxavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT ibanezborja bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis AT fustervalentin bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis |